The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $10.82 down -5.34% from its previous closing price of $11.43. In other words, the price has decreased by -$5.34 from its previous closing price. On the day, 2.02 million shares were traded.
Ratios:
For a deeper understanding of Ginkgo Bioworks Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 5.79. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.56.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 21 ’25 when Che Austin bought 99 shares for $11.70 per share.
Che Austin bought 99 shares of DNA for $1,238 on Feb 20 ’25. On Feb 19 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $13.58 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.85 while its Price-to-Book (P/B) ratio in mrq is 0.68.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $64.40, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is -5.22%, while the 200-Day Moving Average is calculated to be -14.08%.
Shares Statistics:
A total of 41.37M shares are outstanding, with a floating share count of 36.50M. Insiders hold about 33.00% of the company’s shares, while institutions hold 58.55% stake in the company.
Earnings Estimates
The market rating of Ginkgo Bioworks Holdings Inc (DNA) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0. Analysts are recommending an EPS of between -$9.92 and -$9.92 for the fiscal current year, implying an average EPS of -$9.92.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $44.43M this quarter.It ranges from a high estimate of $46.8M to a low estimate of $43.1M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $34.76MFor the next quarter, 5 analysts are estimating revenue of $44.24M. There is a high estimate of $47M for the next quarter, whereas the lowest estimate is $40M.
A total of 6 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $230M, while the lowest revenue estimate was $226.3M, resulting in an average revenue estimate of $227.68M. In the same quarter a year ago, actual revenue was $251.46MBased on 6 analysts’ estimates, the company’s revenue will be $203.81M in the next fiscal year. The high estimate is $220.03M and the low estimate is $190M.
